Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.

American journal of hematology·2026
Same author

Lung cysts, a common feature found in patients with hairy cell leukaemia and Langerhans cell histiocytosis.

ERJ open research·2026
Same author

Central nervous system involvement in multiple myeloma as a first manifestation of relapse and potential diagnostic pitfall.

Cytometry. Part B, Clinical cytometry·2026
Same author

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Blood·2026
Same author

BRAF inhibitor plus rituximab in classical hairy cell leukaemia: A retrospective multicentre real-life study.

British journal of haematology·2026
Same author

Bronchiectasis associated with ulcerative colitis relapse after lung transplantation: a case report.

ERJ open research·2026

Related Experiment Video

Updated: Apr 11, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K

Developing Molecular Signatures for Chronic Lymphocytic Leukemia.

Edouard Cornet1, Agathe Debliquis2, Valérie Rimelen2

  • 1CHU Caen, Laboratory of Hematology, 14000, Caen, France; University of Caen, Medical School, 14000, Caen, France.

Plos One
|June 6, 2015
PubMed
Summary

Researchers developed a gene-expression signature to classify chronic lymphocytic leukemia (CLL). This molecular signature helps differentiate CLL from normal cells and other B-cell disorders, aiding diagnosis and prognosis.

More Related Videos

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

10.7K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.7K

Related Experiment Videos

Last Updated: Apr 11, 2026

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

14.3K
Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

10.7K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.7K

Area of Science:

  • Hematology
  • Molecular Biology
  • Genomics

Background:

  • Chronic lymphocytic leukemia (CLL) is a heterogeneous B-cell malignancy with variable clinical courses.
  • Accurate diagnosis and prognosis are crucial for effective patient management.
  • Identifying reliable molecular markers can improve CLL classification and treatment strategies.

Purpose of the Study:

  • To develop and validate molecular signatures for classifying chronic lymphocytic leukemia (CLL).
  • To distinguish CLL from normal B cells and peripheral blood.
  • To differentiate mutated from unmutated CLL and other B-cell lymphoproliferative disorders.

Main Methods:

  • Utilized digital multiplexed gene-expression (DMGE) technique on a cohort of 30 CLL patients.
  • Analyzed a panel of 290 genes to identify potential diagnostic and prognostic markers.
  • Developed gene signatures for classification: 13 genes (CLL vs. normal), 24 genes (mutated vs. unmutated CLL), and 44 genes (CLL vs. other B-cell disorders).

Main Results:

  • A 13-gene signature successfully distinguished CLL from normal peripheral blood and B cells.
  • A 24-gene signature (LymphCLL Mut) differentiated mutated from unmutated CLL cases.
  • A 44-gene signature (LymphCLL Diag) effectively classified CLL from 51 other B-cell chronic lymphoproliferative disorders.

Conclusions:

  • The developed gene-expression signatures show potential as a 'ready-to-use' classification tool for CLL diagnostics and clinical trials.
  • The DMGE technique offers a robust method for identifying molecular signatures in CLL.
  • Further validation with larger sample sizes is recommended to confirm the robustness and clinical utility of these classifiers.